Contraindicated (1)pentobarbital will decrease the extent or result of lumefantrine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with robust CYP3A4 inducers may end up in reduced serum concentrations and loss of antimalarial efficacypentobarbital will minimize the extent or influence of budesonide by i